RNAZ (TransCode Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


RNAZ TransCode Therapeutics Inc RNAZ
34 GF Score
Price $4.84
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics EBITDA Margin %?

TransCode Therapeutics RNAZ +10.69% 34 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates RNAZ with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, TransCode Therapeutics ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. TransCode Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-17.53 Mil. TransCode Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, TransCode Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

TransCode Therapeutics  (NAS:RNAZ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

TransCode Therapeutics EBITDA Margin % Related Terms

TransCode Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for TransCode Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics EBITDA Margin % Chart

TransCode Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

TransCode Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RNAZ vs ARTL, GLMD, DCOY: EBITDA Margin % Comparison

For the Biotechnology subindustry, TransCode Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransCode Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where TransCode Therapeutics's EBITDA Margin % falls into.


RNAZ
34GF Score
TransCode Therapeutics Inc RNAZ
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

TransCode Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-34.314/0
= %

TransCode Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-17.53/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
TransCode Therapeutics (RNAZ) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TransCode Therapeutics and its competitors. According to the industry distribution chart, TransCode Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry.
Is TransCode Therapeutics' EBITDA Margin % too high?
TransCode Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, TransCode Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TransCode Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' EBITDA Margin % compare to ARTL and GLMD?
According to the Biotechnology industry distribution chart, TransCode Therapeutics ranks #999999 out of 944 companies for EBITDA Margin %. This places TransCode Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TransCode Therapeutics and its competitors. TransCode Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. TransCode Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
34GF Score

Get the complete analysis for RNAZ

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.84
Price